Use of Cladribine for multiple sclerosis treatment: An image article

Submitted: 10 February 2021; Accepted: 17 February 2021; Published online: 28 February 2021

Jeniffer Stewert*

*Oncotelic Inc., Agoura Hills, USA

Editorial Office, Clinical Investigation, London, UK

*Author for correspondence: stewertj@hotmail.com

Figure 1: Cladribine reaches the cell via proteins that hold nucleoside. Cladribine is activated within the cell by three subsequent phosphorylations, the first being deoxycytidine kinase. The enzyme 5’-nucleotidase (5’-NTase), active cladribine can be inactivated by dephosphorylation. Lymphocytes have a strong deoxycytidine kinase content and a low 5’-NTase concentration relative to other cells and thus have higher phosphorylated molecule concentrations that are stuck within the cell contributing to preferential phosphorylated, or triggered, cladribine aggregation.